In addition, irinotecan or its active metabolite is administered in different pharmaceutical forms, in monotherapy or combined with other drugs in different therapeutic regimens, at different doses regardless of the patient’s UGT1A1 genotype, and in the treatment of different cancer streams. Here, UGT1A1 is linked to cancer.